PMID: 26536001
Question: Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Correct Answer: no

======================= Launch the MCC process =======================
PMID: 26536001
Question: Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content:** The question seeks to determine whether somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) provides additional predictive value over somatostatin receptor scintigraphy (SRS) uptake (using OctreoScan®) in forecasting the response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to peptide receptor radiotherapy (PRRT) with 177Lu-octreotate.
- **Key Information to Look For:**
  - Percentage of sst2a IHC positivity in GEP-NET samples.
  - The relationship between sst2a IHC status and tumor response after PRRT.
  - Comparison of patient characteristics based on sst2a IHC status.
  - Statistical significance of the findings.

**2. Evidence Evaluation**
- **Research Results:**
  - **sst2a IHC Positivity:** 93% of GEP-NET samples were sst2a IHC positive.
  - **Predictive Relationship:** No statistically significant relationship was found between sst2a expression and tumor response one year post-PRRT (p = 0.47).
  - **Patient Characteristics:** No significant differences in most characteristics between sst2a IHC-negative and -positive groups, except for age at diagnosis (p = 0.007).
- **Strength and Reliability:**
  - The study included 73 consecutive patients, providing a reasonable sample size.
  - The use of RECIST 1.0 criteria offers a standardized method for assessing tumor response.
  - The high percentage of sst2a positivity (93%) suggests limited variability, potentially affecting the ability to detect differences.
- **Relevance to the Question:**
  - Directly addresses whether sst2a IHC adds predictive value over SRS uptake.
  - Findings indicate that sst2a IHC does not significantly enhance prediction beyond what SRS provides.

**3. Conclusion**
Based on the study's findings, sst2a IHC does not offer additional predictive value over SRS uptake in forecasting tumor response to PRRT in GEP-NET patients.

**4. Final Answer**
**My final choice is: "no"**
GPT selected: no

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The core question asks whether sst2a IHC provides additional predictive value beyond SRS (OctreoScan®) for response to PRRT in GEP-NETs. Key information to assess includes: (1) the relationship between sst2a IHC and treatment response, and (2) whether sst2a IHC adds value beyond SRS, given that all patients were selected for PRRT based on positive SRS.  

**2. Evidence Evaluation**  
- **Study Results**:  
  - 93% of tumors were sst2a IHC-positive.  
  - No statistically significant association was found between sst2a IHC expression and tumor response (RECIST 1.0) 1 year post-PRRT (p = 0.47).  
  - Patient characteristics (e.g., sex, tumor site, stage, Ki-67 index) did not differ between sst2a-negative and -positive groups except for age at diagnosis.  
- **Strength/Reliability**: The study included 73 consecutive patients, ensuring real-world applicability. The primary endpoint was directly addressed, and statistical analysis (p-value) was reported.  
- **Relevance**: The results directly address whether sst2a IHC adds predictive value beyond SRS, as all patients had prior positive SRS.  

**3. Conclusion**  
The study demonstrates no additional predictive value of sst2a IHC over SRS for PRRT response. The lack of statistical significance (p = 0.47) and the abstract’s explicit conclusion confirm this.  

**4. Final Answer:**  
**My final choice is: "no"**
Qwen selected: no

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) provides **additional predictive value** over somatostatin receptor scintigraphy (SRS) uptake (OctreoScan®) for predicting tumor response to PRRT in GEP-NETs. Key information to evaluate includes:  
- Comparison of sst2a IHC results with SRS-based patient selection.  
- Statistical relationship between sst2a IHC and radiological response (RECIST 1.0).  
- Study conclusions about the utility of sst2a IHC vs. SRS.

**2. Evidence Evaluation**  
- **Study Design**: 73 PRRT-treated patients (selected based on **positive SRS**) were analyzed. sst2a IHC was performed on tumor samples, and response was assessed via RECIST 1.0 at 1 year.  
- **Results**:  
  - 93% of tumors were sst2a IHC-positive.  
  - **No significant association** between sst2a IHC positivity and tumor response (p = 0.47).  
  - Patient characteristics (e.g., Ki-67, tumor stage) did not differ between sst2a-negative and -positive groups except for age.  
- **Conclusion**: The abstract explicitly states that sst2a IHC has **no additional value** compared to SRS in predicting PRRT response.  

**3. Conclusion**  
The study demonstrates that sst2a IHC does not improve predictive accuracy beyond SRS in this cohort. Since all patients were pre-selected via SRS (which already reflects sst2a functionality) and no statistical link was found between sst2a IHC and response, the evidence strongly supports **no additional value** for sst2a IHC.  

**4. Final Answer**  
**My final choice is: no**
DeepSeek selected: no

Initial consensus: All models selected no